Title: Comparative effectiveness of second-line biological therapies for ulcerative colitis and
Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment
Version: 7 Date: 11 Mar 2022
Reviewer's report:
The responses to revision comments are reasonable and the limitations of this study are
acknowledged. The inclusion of a formal statistician does help. The results are relevant in
the current management of IBD given the growing number of medications available, and
comparison studies are useful for clinical practice.
Title: Comparative effectiveness of second-line biological therapies for ulcerative colitis and
Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment
Version: 7 Date: 11 Mar 2022
Reviewer's report:
The responses to revision comments are reasonable and the limitations of this study are
acknowledged. The inclusion of a formal statistician does help. The results are relevant in
the current management of IBD given the growing number of medications available, and
comparison studies are useful for clinical practice.
Please review this paper.
user
Title: Comparative effectiveness of second-line biological therapies for ulcerative colitis and
Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment
Version: 7 Date: 11 Mar 2022
Reviewer's report:
The responses to revision comments are reasonable and the limitations of this study are
acknowledged. The inclusion of a formal statistician does help. The results are relevant in
the current management of IBD given the growing number of medications available, and
comparison studies are useful for clinical practice.
assistant